Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure - Special reference to atrial fibrillation

Circulation Journal

Volumn 74, Issue 6, 2010, Pages 1127-1134

  Konishi, Masanori ^a   Haraguchi, Go ^a   Kimura, Shigeki ^a   Inagaki, Hiroshi ^a   Kawabata, Mihoko ^a   Hachiya, Hitoshi ^a   Hirao, Kenzo ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Beta blocker; Heart failure; Japanese

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL;

AGED; ARTICLE; BLOOD ANALYSIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEFIBRILLATION; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SINUS RHYTHM;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BISOPROLOL; CARBAZOLES; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROPANOLAMINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77953513994     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0989     Document Type: Article

References (30)

1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.
2. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-1446.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
4. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996; 94: 2807-2816.
5. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
6. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199.
7. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7-13.
8. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
9. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS): CIBIS Investigators and Committees. Circulation 1994; 90: 1765-1773.
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
11. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426-2435.
12. Hampton JR. Results of clinical trials with diuretics in heart failure. Br Heart J 1994; 72: S68-S72.
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
14. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-1435.
15. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
16. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
17. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
18. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-recep-tor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
20. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
21. Schafers RF, Poller U, Ponicke K, Geissler M, Daul AE, Michel MC, et al. Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 239-249.
22. McDevitt DG. In vivo studies on the function of cardiac beta-adre-noceptors in man. Eur Heart J 1989; 10: 22-28.
23. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure-special reference to ranscardiac gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
24. Tsuboi J, Kawazoe K, Izumoto H, Okabayashi H. Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. Circ J 2008; 72: 588-591.
25. Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Krackhardt F, Pavlovic M, et al. Bisoprolol vs. carvedilol in elderly patients with heart failure: Rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 2008; 97: 578-586.
26. Asanuma H, Minamino T, Sanada S, Takashima S, Ogita H, Ogai A, et al. Beta-adrenoceptor blocker carvedilol provides cardiopro-tection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 2004; 109: 2773-2779.
27. Ishiguro H, Ikeda T, Abe A, Tsukada T, Mera H, Nakamura K, et al. Antiarrhythmic effect of bisoprolol, a highly selective betal-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49: 28l-293.
28. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009; 73: 295-298.
29. Wyse DG. Pharmacologic approaches to rhythm versus rate control in atrial fibrillation-where are we now? Int J Crdiol 2006; 110: 30l-3l2.
30. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008; 10: 446-453.